Form 4: Oramed Pharmaceuticals CFO Avraham Gabay Receives 30,000 Restricted Stock Units

Avraham Gabay, CFO of Oramed Pharmaceuticals, reports the acquisition of 30,000 Restricted Stock Units (RSUs) that vest on November 7, 2024.

Summary

• Avraham Gabay, the Chief Financial Officer of Oramed Pharmaceuticals Inc., filed a Form 4 on November 8, 2024.
• The form reports a transaction that occurred on November 7, 2024, where Mr. Gabay acquired 30,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs will vest on November 7, 2024, and convert into Common Stock on a one-for-one basis.
• Following this transaction, Mr. Gabay directly owns 170,040 shares of Oramed Pharmaceuticals Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock options, which is neither particularly positive nor negative.

Positives

• The grant of RSUs to the CFO could be seen as a positive sign, aligning his interests with those of the shareholders.

Future Outlook

The vesting of the RSUs on November 7, 2024, will result in the issuance of 30,000 shares of common stock to Mr. Gabay.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the transactions of company executives and directors.

Stakeholder Impact

• The transaction could have a minor dilutive effect on existing shareholders when the RSUs vest and convert to common stock.

Key Dates